Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Sangamo Therapeutics
Modality
gene_therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05039866CT.gov Long-Term Follow-up of Subjects Who Were Treated With ST-920 | — | Enrolling By Invitation | — | — | — |
NCT04046224CT.gov Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fabry Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isaralgagene Civaparvovec (this asset) | Sangamo Therapeutics | P1/2 | CCC · 50 |
| Recombinant Alpha-Galactosidase A | Shire | P4 | A |
| Agalsidase Beta | Sanofi | P4 | A |
| Pegunigalsidase Alfa | Chiesi Italia | P3 | BBB |
| Migalastat | Amicus Therapeutics | P3 | BBB |
| Montelukast | Sanofi | P4 | BB |
| Fexofenadine | Sanofi | P4 | BB |
| Loratadine | Sanofi | P4 | BB |
| Lucerastat | Idorsia Pharmaceuticals Ltd. | P3 | BB |
+28 more in the Fabry Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Isaralgagene Civaparvovec in Fabry Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/isaralgagene-civaparvovec-fabry-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →